Evodiamine regulates osteoclast differentiation and inhibits bone loss

王继荣,暴一众,唐颖,吕晓玲,杨舟鑫

DOI: https://doi.org/10.3877/cma.j.issn.2095-1221.2022.02.004

2022-01-01

Abstract:Objective:To investigate the regulation of evodiamine on osteoclast (OC) differentiation and bone resorption, and its therapeutic effect on osteoporosis.Methods:The mouse primary bone marrow-derived macrophages were treated with 0, 10, 20, 50, 100, 200 μmol/L evodiamine respectively, and the cell viability was detected by CCK8. Primary bone marrow-derived macrophages were used to induce osteoclast differentiation in mice by administering recombinant soluble nuclear factor-κB receptor activator factor and colony-stimulating factor, and were intervened by 20 and 50 μmol/L evodiamine, respectively. The formation ability of osteoclasts was detected by tartrate-resistant acid phosphatase (TRAP) staining, the expression of osteoclast differentiation-related genes was analyzed by fluorescence quantitative PCR, the formation of F-actin was detected by immunofluorescence, and the bone resorption ability of osteoclasts was observed by scanning electron microscope. 7-month-old C57BL/6 mice were orally administrated with evodiamine daily at 100 or 200 mg/kg for 3 months. Bone density and bone quality of the mice were measured by Micro-CT. One-way ANOVA and t-test was used for statistical analysis.Results:Compared with the control group, CCK8 results showed that there was no significant change in cell viability in the 10, 20, 50, and 100 μmol/L evodiamine-treated groups, and the difference was not statistically significant (P > 0.05) . 200 μmol/L evodiamine inhibited the cell viability (100.64±0.18 vs 47.54±5.58) , and the difference was statistically significant (P < 0.01) . 20 μmol/L evodiamine decreased the number of TRAP staining positive cells (200.57±28.35 vs 142.29±19.21) , the mRNA levels of Trap (1.00±0.13 vs 0.55±0.16) and cathepsin K (Ctsk) (1.01±0.17 vs 0.59±0.11) , the area of bone resorption (1.00±0.15 vs 0.79±0.19) , compared with the control group, and the difference was statistically significant (P < 0.05) . 50 μmol/L evodiamine reduced the number of TRAP staining positive cells (200.57±28.35 vs 112.71±12.18) , the mRNA levels of Trap (1.00±0.13 vs 0.46±0.17) , Ctsk (1.01±0.17 vs 0.49±0.12) , DC-Stamp (1.00±0.10 vs 0.55±0.14) , c-Fos (1.01±0.10 vs 0.58±0.14) , Nfatc1 (1.00±0.10 vs 0.59±0.14) and Atp6v0d2 (1.00±0.10 vs 0.59±0.18) , the number of F-actin (165.00±18.50 vs 98.33±21.15) and bone resorption area was also decreased (1.00±0.15 vs 0.62±0.10) , and the difference was statistically significant (P < 0.05) . Micro-CT results showed the bone density of the mice in the 100 mg/kg evodiamine group were somewhat elevated compared with control group [ (0.19±0.03) vs (0.21±0.01) g/cm3], but the difference was not statistically significant (P > 0.05) .The bone density [ (0.19±0.03) vs (0.23±0.01) g/cm3], bone volume ratio[ (9.79±1.39) ﹪ vs (11.62±1.18) ﹪], and the number of trabecular bones[ (2.43±0.29) vs (3.08±0.43) mm] in the evodiamine 200 mg/kg group were increased, and the separation of trabecular bones[ (0.44±0.06) vs (0.27±0.05) mm] was decreased, compared with the control group, and the difference was statistically significant (P < 0.05) .Conclusion:Evodiamine inhibited bone loss by inhibiting osteoclast differentiation and bone resorption.